文献速递糖尿病

连续葡萄糖监测指导住院糖尿病患者胰岛素给药:一项随机临床试验

Continuous Glucose Monitoring-Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial.
PubMed 文献 · Diabetes Care · 2022-01-01

这项随机试验纳入185例接受基础-餐时胰岛素方案治疗的普通内科和外科1型及2型糖尿病患者,比较持续葡萄糖监测(CGM)指导与床旁(POC)毛细血管血糖指导的胰岛素调整。两组在目标范围内时间(TIR)和低血糖发生率上无显著差异,但在发生至少一次低血糖事件的患者中,CGM组低血糖复发事件显著减少。

要点

  • CGM指导与POC指导的TIR无显著差异(54.51% vs 48.64%,P=0.14)。
  • CGM组与POC组低血糖发生率无显著差异(<70 mg/dL:36% vs 39%;<54 mg/dL:14% vs 24%)。
  • 在发生低血糖事件的患者中,CGM组低血糖复发事件显著少于POC组(1.80 vs 2.94事件/患者,P=0.03)。

核心结论

  • 住院患者使用实时Dexcom G6 CGM指导胰岛素治疗安全有效,与POC指导相比血糖控制改善程度相似,且显著减少复发性低血糖事件。

研究设计与样本

  • 随机临床试验,纳入185例接受基础-餐时胰岛素方案治疗的普通内科和外科1型及2型糖尿病患者。
  • 所有受试者均在餐前和睡前进行床旁(POC)毛细血管血糖检测。
  • 标准治疗组(POC组)佩戴盲法Dexcom G6 CGM,根据POC结果调整胰岛素剂量;CGM组根据每日CGM图谱调整胰岛素。
  • 主要终点为目标范围内时间(TIR;70-180 mg/dL)和低血糖(<70 mg/dL及<54 mg/dL)的差异。

主要发现

  • CGM指导组与POC组TIR无显著差异(54.51% ± 27.72 vs 48.64% ± 24.25;P=0.14)。
  • CGM指导组与POC组平均每日血糖无显著差异(183.2 ± 40 vs 186.8 ± 39 mg/dL;P=0.36)。
  • CGM指导组与POC组CGM值<70 mg/dL的患者百分比无显著差异(36% vs 39%;P=0.68),<54 mg/dL的患者百分比也无显著差异(14% vs 24%;P=0.12)。
  • 在发生一次或以上低血糖事件的患者中,与POC组相比,CGM组低血糖复发显著减少(1.80 ± 1.54 vs 2.94 ± 2.76事件/患者;P=0.03)。
  • 在发生一次或以上低血糖事件的患者中,CGM组低于范围<70 mg/dL的时间百分比显著低于POC组(1.89% ± 3.27 vs 5.47% ± 8.49;P=0.02)。

临床怎么用

  • 住院患者使用实时Dexcom G6 CGM指导胰岛素治疗安全有效,与POC指导相比血糖控制改善程度相似,且显著减少复发性低血糖事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The efficacy and safety of continuous glucose monitoring (CGM) in adjusting inpatient insulin therapy have not been evaluated. RESEARCH DESIGN AND METHODS: This randomized trial included 185 general medicine and surgery patients with type 1 and type 2 diabetes treated with a basal-bolus insulin regimen. All subjects underwent point-of-care (POC) capillary glucose testing before meals and bedtime. Patients in the standard of care (POC group) wore a blinded Dexcom G6 CGM with insulin dose adjusted based on POC results, while in the CGM group, insulin adjustment was based on daily CGM profile. Primary end points were differences in time in range (TIR; 70-180 mg/dL) and hypoglycemia (<70 mg/dL and <54 mg/dL). RESULTS: There were no significant differences in TIR (54.51% ± 27.72 vs. 48.64% ± 24.25; P = 0.14), mean daily glucose (183.2 ± 40 vs. 186.8 ± 39 mg/dL; P = 0.36), or percent of patients with CGM values <70 mg/dL (36% vs. 39%; P = 0.68) or <54 mg/dL (14 vs. 24%; P = 0.12) between the CGM-guided and POC groups. Among patients with one or more hypoglycemic events, compared with POC, the CGM group experienced a significant reduction in hypoglycemia reoccurrence (1.80 ± 1.54 vs. 2.94 ± 2.76 events/patient; P = 0.03), lower percentage of time below range <70 mg/dL (1.89% ± 3.27 vs. 5.47% ± 8.49; P = 0.02), and lower incidence rate ratio <70 mg/dL (0.53 [95% CI 0.31-0.92]) and <54 mg/dL (0.37 [95% CI 0.17-0.83]). CONCLUSIONS: The inpatient use of real-time Dexcom G6 CGM is safe and effective in guiding insulin therapy, resulting in a similar improvement in glycemic control and a significant reduction of recurrent hypoglycemic events compared with POC-guided insulin adjustment.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Spanakis EK, Urrutia A, Galindo RJ, et al. Continuous Glucose Monitoring-Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial. Diabetes Care. 2022. PMID: 35984478. doi:10.2337/dc22-0716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。